Feasibility of an IL-17a Assay and Its Impact on Treatment Response in Patients With Active Axial Spondyloarthritis

What this Trial Is About

Researchers are investigating spondyloarthritis (SpA), a condition causing joint inflammation, to better understand how to choose the best biological treatment for patients with active disease. Currently, no validated biomarkers or direct comparison studies exist to guide the choice between different biologic agents like TNF inhibitors and IL-17 inhibitors. This study aims to assess whether measuring certain immune proteins, specifically IL-17, after stimulating immune cells can help predict how well patients respond to biological treatment. Participants in this observational study will have blood samples taken to measure IL-17 levels following lymphocyte stimulation. The study involves patients with active SpA who require biological treatment after failing at least two non-steroidal anti-inflammatory drugs (NSAIDs). The primary goal is to demonstrate that this cytokine test is feasible, and secondly, to determine if IL-17 levels can predict treatment response three months after starting biological therapy. During the 18-month study period, researchers will collect and analyze blood samples to perform the IL-17 assay. They will monitor patient disease activity and treatment outcomes to understand the relationship between cytokine levels and therapeutic response. This approach aims to provide a useful tool to support personalized treatment decisions in active SpA, improving how biological therapies are chosen and managed.

IL17 Rate and Spondyloarthritis